Video

Progression on Frontline Ibrutinib in CLL

Transcript:

Related Videos
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
David L. Porter, MD
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Carrie L. Kitko, MD
Lori A. Leslie, MD
Jean L. Koff, MD, MS
Lori A. Leslie, MD
Changchun Deng, MD, PhD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University
May 31st 2024

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Janet Abrahm, MD, FACP, FAAHPM, of Dana-Farber Cancer Institute
May 27th 2024

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Sanjal Desai, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota
May 24th 2024

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

Katie S. Gatwood, PharmD, BCOP, a clinical pharmacist specialist in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center
May 24th 2024

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies